JPRN-UMIN000043663已完成未知
The exploratory study to evaluate biomarkers in prospective multicenter observational study of atezolizumab combination therapy in patients with unresectable, advanced and recurrent non-small cell lung cancer or extensive disease small cell lung cancer (J-TAIL-2) - The biomarker exploratory study in prospective multicenter observational study of atezolizumab combination therapy in lung cancer (J-TAIL-2)
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 450
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •< non-small cell lung cancer cohort> (1) Patients who are unsuitable for enrolment into the study by the investigator's judgment. <extensive disease small cell lung cancer cohort> (1) Patients who are unsuitable for enrolment into the study by the investigator's judgment.
研究者
相似试验
已完成
不适用
Exploratory study to investigate biomarkers associated with pathogenesis of infantile hemangioma.Infantile hemangiomaJPRN-UMIN000038574Wakayama Medical University45
尚未招募
Unknown
Exploratory research of biomarkers for investigational drugs using tear fluid samplesMeibomian Gland DysfunctionJPRN-UMIN000049186Santen Pharmaceutical Co. Ltd.29
招募中
不适用
An exploratory prospective study of the biomarkers of the immune-related adverse events (irAE) and the mechanisms of irAE in solid cancer patients treated with Pembrolizumab.solid cancerJPRN-UMIN000028474Department of Internal Medicine, Division of Medical Oncology, Showa University School of Medicine.30
招募中
不适用
An exploratoly study to evaluate biomarkers in cell free DNA of "Sequential therapy from afatinib to osimertinib for EGFR mutant non small cell lung cancer: a multicenter prospective observational study (Gio Tag Japan)".non-small cell lung cancer(EGFR mutation positive)JPRN-UMIN000043235HANSHIN Oncology Group93
已完成
不适用
An exploratory study to evaluate biomarkers as predictive and /or prognostic factors of benefit from randomized phase ll study of mFOLFOX6+bevacizumab or mFOLFOX6+cetuximab in liver only metastasis from KRAS wild type colorectal cancerliver only metastasis from KRAS Exon 2 wild type (under protocol 1.0-1.2 edition) and RAS wild type (under protocol 2.0 edition) colorectal cancerJPRN-UMIN000010429EPS Corporation100